Exagen Inc. Partners with Oregon’s St. Charles Health System to Offer AVISE® Testing as an In-Network Benefit for Patients...
January 04 2021 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, announced today that all AVISE test offerings
(CTD, Lupus, SLE Prognostic, SLE Monitor, APS, Vasculitis AAV, MTX,
and HCQ) are a contracted in-network service with St. Charles
Health System, the largest provider of medical care in Central
Oregon.
“St. Charles has a far-reaching impact on the health and
wellbeing of the communities they serve. As the largest employer in
the region, providing access to AVISE testing will play an
important part in enabling rheumatologists to improve patient care
through the differential diagnosis, prognosis and monitoring of
complex autoimmune diseases, including SLE,” said Ron Rocca,
President and CEO of Exagen.
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable providers to improve care for patients
through the differential diagnosis, prognosis and monitoring of
complex autoimmune and autoimmune related diseases, including
rheumatoid arthritis and lupus. For further information please
visit www.exagen.com.
About St. Charles Health System
Headquartered in Bend, OR, St. Charles Health System, Inc., owns
and operates St. Charles Bend, Madras, Prineville and Redmond. It
also owns family care clinics in Bend, La Pine, Madras, Prineville,
Redmond and Sisters. St. Charles is a private, not-for-profit
Oregon corporation and is the largest employer in Central Oregon
with more than 4,500 caregivers. In addition, there are more than
350 active medical staff members and nearly 200 visiting medical
staff members who partner with the health system to provide a wide
range of care and service to our communities.
Forward Looking Statements
Exagen cautions you that statements in this press release that
are not a description of historical facts are forward-looking
statements. These statements are based on the Company's current
beliefs and expectations. Such forward-looking statements include,
but are not limited to, statements regarding the expected benefits
of the positive medical policy coverage for the AVISE test
offerings with St. Charles Health System, including the
availability and expected use of the AVISE test offerings through
the St. Charles Health System network, and any potential for
increased use of the AVISE laboratory tests. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: the COVID-19 pandemic may
continue to adversely affect our business, financial condition and
results of operations, including as a result of shutdowns of our
facilities and operations as well as those of our suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for our tests, our sales and
commercialization activities and our ability to receive specimens
and perform or deliver the results from our tests, delays in
reimbursement and coverage decisions from Medicare and third-party
payors and in interactions with regulatory authorities, and delays
in ongoing and planned clinical trials involving our tests; the
company’s commercial success depends upon attaining and maintaining
significant market acceptance of its testing products and promoted
therapeutics among rheumatologists, patients, third-party payers
and others in the medical community; the company’s ability to
successfully execute on its Dx/Rx strategy, including its promotion
efforts for SIMPONI®; third party payers not providing coverage and
adequate reimbursement for the company’s testing products or
promoted therapeutics; the company’s ability to obtain and maintain
intellectual property protection for its testing products;
regulatory developments affecting the company’s business; and other
risks described in the company’s prior press releases and the
Company’s filings with the Securities and Exchange Commission
(SEC), including under the heading “Risk Factors” in the company’s
Annual Report on Form 10-K and any subsequent filings with the SEC.
You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com 646.677.1838
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024